Neurodegenerative Disease
83
19
23
33
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.4%
7 terminated out of 83 trials
82.5%
-4.0% vs benchmark
2%
2 trials in Phase 3/4
9%
3 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (83)
A Phase 3 Study of NTLA-2001 in ATTRv-PN
The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
3D Printers for Autonomy in the Care of Inpatients in Continuing and Rehabilitation Care
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers
Cross Cultural Validation of the Italian Version of the Clinical Assessment of Dysphagia in Neurodegeneration
Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity
Kamlanoflast In Amyotrophic Lateral Sclerosis
Retinal Imaging in Neurodegenerative Disease
Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research
Eccentric Cycling in Multiple Sclerosis Rehabilitation
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
[18F]NIDF PET Imaging in Tau-related Diseases
Mindfulness Walking Intervention to Enhance Resilience (iWalk)
Tocotrienols in Parkinson's Disease (PD)
Conventional Physical Therapy Action Observation Therapy on Freezing of Gait and Functional Mobility in Parkinson's Disease
Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects